SCHEMBL6334129

SCHEMBL6334129

O=C(Cc1ccccc1F)N1CC(N2CCOCC2)CN1C(=O)c1ccnc(Oc2ccccc2)n1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CPT1A P50416 1/20 0.36
SCN9A Q15858 3/20 0.35
ACHE P22303 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.34
CNR1 P21554 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MMP1 P03956 1/20 0.33
MMP3 P08254 1/20 0.33
MMP7 P09237 1/20 0.33
POLB P06746 1/20 0.33
FKBP1A P62942 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
MGLL Q99685 1/20 0.32
AOC3 Q16853 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4851295 0.89 MAPK14 (0.40) CPT1ASCN9AACHESCN10AALDH1A1
SCHEMBL4861342 0.76 MAPK14 (0.37) CPT1AFKBP1AKDM4ELMNA
SCHEMBL27537569 0.72 MAPK14 (0.41) CPT1ANPC1ALDH1A1FKBP1AKDM4E
SCHEMBL14269365 0.68 ALDH1A1 (0.44) NPC1RAB9AALDH1A1POLBKDM4E
SCHEMBL4859042 0.63 MAPK14 (0.53)
SCHEMBL27561304 0.63 MAPK14 (0.38) SCN9ANPC1ALDH1A1FKBP1AKDM4E
SCHEMBL4857310 0.62 MAPK8 (0.56) KDM4ELMNA
SCHEMBL4852539 0.62 MEN1 (0.49) NPC1RAB9AALDH1A1KDM4ELMNA
Hydrochloric Acid SCHEMBL4857845 0.61 MEN1 (0.48) NPC1RAB9AALDH1A1KDM4ELMNA
SCHEMBL4850980 0.60 MAPK8 (0.50) SCN9ANPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849627-B2 Including interleukin-1 and Tumor Necrosis Factor; treating rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, septic shock, cardiopulmonary dysfunction, acute respiratory disease, and cachexia THE PROCTER & GAMBLE COMPANY (US) 2005-02-01 US disclosed